Giant Biogene Holding Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in Xi'an in 2000 to a Hong Kong IPO on November 4, 2022, Giant Biogene Holding Co., Ltd. has grown into a domestic leader in recombinant collagen-based skin treatment and rare ginsenosides functional foods: the company reported annual revenue of 5.54 billion CNY in 2024, a striking 57.17% year‑on‑year increase, operates a portfolio of 106 SKUs across brands like Comfy, Collgene, Ke Yu and SKIGIN, and employed 1,758 staff as of June 30, 2025; with controlling shareholder Juzi Holding raising its stake to 54.66% after an October 27, 2025 purchase of 4,226,600 shares for about HK$200.2 million, a market capitalization of HK$42.15 billion (as of November 14, 2025), analyst Buy ratings and HK$44.60-HK$78.00 price targets, plus a newly approved Recombinant Type I α1 Subtype Collagen Freeze‑dried Fibers product in October 2025, the company's strategy, ownership moves, revenue drivers and product pipeline make it a must‑read case study for investors and industry watchers alike-dive into the full article to explore Giant Biogene's history, governance, business model and paths to growth.

Giant Biogene Holding Co., Ltd. (2367.HK): Intro

• Core technology: recombinant collagen production and formulation for topical, injectable and implantable uses.
• Key activities: R&D, proprietary manufacturing, clinical/quality compliance, domestic and export sales, and channel distribution to hospitals, aesthetic clinics and retail.
• Corporate milestones: incorporated in the Cayman Islands in 2020 and listed on the Hong Kong Stock Exchange (ticker 2367.HK) on November 4, 2022.

• Product sales - primary revenue from recombinant-collagen-based skin repair and aesthetic products sold to hospitals, clinics and distributors.
• Contract manufacturing - GMP production services for partners and private-label orders.
• R&D-driven pipeline - monetization via new product launches and potential licensing of proprietary formulations and processes.
• After-sales and channels - training, clinical support and service contracts that enhance product adoption and recurring purchases.

• Vertical integration: in-house recombinant collagen synthesis, formulation labs and production lines to control quality and margins.
• Growth drivers: expanding domestic aesthetic market, higher clinical adoption, broader hospital tender wins and export opportunities.
• Capital structure/market access: Cayman Islands incorporation facilitates international capital flows and enabled the HKEX listing in 2022.

Giant Biogene Holding Co., Ltd. (2367.HK): History

• Controlling shareholder: Juzi Holding Co., Ltd.
• Key transaction announced: October 27, 2025 - Juzi increased its stake to 54.66%.
• Acquisition details: Purchased 4,226,600 additional shares for approximately HK$200.2 million.
• Share-building timeline: Juzi had been gradually increasing its stake since June 2025 prior to the October purchase.
• Stated intent: Strengthen stability, safeguard public investors' interests and support sustainable growth.

• Research & development: discovery and clinical development of biologics and therapeutics.
• Manufacturing & supply: production of biologic drug substances and finished products for sale/license.
• Commercialization: direct sales, distribution partnerships and licensing deals in regional markets.
• Services & diagnostics: revenue from diagnostic kits, testing services and contract manufacturing.

• Pipeline value and milestone/royalty payments drive long-term revenue potential.
• Manufacturing capacity utilization affects gross margins and cash generation.
• Partnerships/licensing accelerate market access while de‑risking late‑stage costs.
• Share consolidation by Juzi aims to improve governance stability and investor confidence.

Giant Biogene Holding Co., Ltd. (2367.HK): Ownership Structure

• Mission: Research, development, manufacture and sale of professional skin treatment products using recombinant collagen; development and manufacturing of rare ginsenosides technology-based functional foods.
• Values: Sustainable growth, consumer satisfaction, continuous improvement, and rigorous quality control.
• Market focus: Primarily domestic (Mainland China) distribution, R&D-driven product development, and regulatory compliance for cosmetics and health-food sectors.

• R&D prioritization: owners back continued investment in recombinant collagen and rare ginsenoside platforms to sustain product differentiation.
• Manufacturing control: proprietary production processes and quality systems to protect margins and brand trust.
• Domestic commercialization: distribution and marketing geared to Chinese consumer channels (dermal clinics, beauty retailers, e‑commerce).

Giant Biogene Holding Co., Ltd. (2367.HK): Mission and Values

• Core product technologies: recombinant collagen for skin treatment, rare ginsenosides extraction/formulation, and medical dressing/device manufacturing.
• Brands and positioning: Comfy, Collgene, Ke Yu, SKIGIN and others targeting functional skincare, clinical/medical dressing solutions, and health-oriented functional foods.
• Market focus: predominantly domestic China sales with export activities limited relative to the domestic footprint.

• R&D and formulation: internal teams develop recombinant collagen technologies and rare ginsenosides-based formulations; pilot and scale-up occur in company-controlled facilities.
• Manufacturing: in-house production for key SKUs and contract manufacturing for selected lines to manage capacity and cost.
• Brand and distribution: multi-brand strategy covering retail, e-commerce, cosmetic clinics, and hospital/medical procurement channels.
• Regulatory & quality: medical dressings and devices follow clinical/medical device registration pathways while cosmetics and functional foods follow CFDA/NMPA pathways for compliance in China.

• Finished goods sales: retail and e-commerce sales of branded skincare and functional foods (primary revenue driver).
• Institutional sales: hospitals, clinics and medical procurement for medical dressings and devices (higher average order value, B2B contracts).
• OEM/contract manufacturing: selected external customers leveraging Giant Biogene's recombinant collagen and ginsenoside technology (supplementary margin stream).
• Licensing and IP: technology licensing and joint-development arrangements for recombinant collagen applications and ginsenoside extraction technologies (strategic, variable revenue).

• SKU breadth: 106 SKUs across eight major brands enables multi-segment coverage and cross-selling opportunities.
• Domestic concentration: over 90% of revenue generated within China (focus on tier-1 to tier-3 city distribution and e-commerce penetration).
• Margin structure: consumer-facing skincare and functional foods deliver gross-margin mix distinct from medical device margins (skincare higher margin; medical devices more stable recurring institutional orders).
• R&D intensity: ongoing investment in recombinant collagen and rare ginsenoside extraction/process optimization to sustain product differentiation and defend margins.

• Proprietary material science (recombinant collagen) enabling targeted skin-repair products with clinical positioning.
• Functional foods leveraging rare ginsenosides technology for health-focused consumer segments.
• Integrated capability from R&D to manufacturing to branded sales, allowing faster product cycles and quality control for medical/clinical channels.

Giant Biogene Holding Co., Ltd. (2367.HK): How It Works

• Core bioactive technologies: recombinant human-like collagen (key for dermal repair, anti-aging formulations) and rare ginsenosides extraction/biotransformation (functional food and health supplements).
• Main product categories:
  • Functional skincare (serums, masks, creams leveraging recombinant collagen)
  • Medical dressings and wound-care products (collagen-based dressings, hydrogel products)
  • Functional foods and nutraceuticals (ginsenoside-enriched supplements, capsules, drinks)
• Primary market: domestic China-retail, e-commerce, hospital/clinic procurement and institutional supply chains.
• Distribution channels: online marketplaces, specialty cosmetics stores, pharmacy chains, hospitals and direct B2B contracts.
• R&D and manufacturing model: vertically integrated-own production lines for recombinant collagen and downstream formulation, allowing control over quality, COAs and margins.

• How products translate to revenue:
  • Skincare and cosmetics: premium pricing on collagen-enriched products with higher gross margins due to patented bioactive claims and brand positioning.
  • Medical dressings: hospital tenders and long-term supply contracts yield stable B2B revenue and recurring orders.
  • Functional foods/supplements: volume-driven sales through e-commerce and pharmacy chains, leveraging rare ginsenosides for differentiation.
• Value chain advantages:
  • Proprietary production of recombinant collagen reduces reliance on third-party suppliers and supports faster product development.
  • Integrated R&D enables formulation upgrades and IP-driven premium SKUs.
  • Domestic focus reduces export-related regulatory friction and concentrates marketing/infrastructure spend.
• Key financial/operational levers: pricing of premium SKUs, expansion of e-commerce penetration, higher-margin B2B hospital contracts, and scale-driven cost reductions in bioactive production.

Giant Biogene Holding Co., Ltd. (2367.HK): How It Makes Money

• Primary revenue streams: sale of professional skin treatment products (including bioactive ingredients and finished goods), medical aesthetic devices, consumables (including single-use collagen fibers), and licensing/technology collaborations with clinics and distributors.
• Channel mix: direct sales to medical aesthetic clinics and hospital dermatology departments, wholesale to spa and beauty chains, and partnerships with distributors for domestic and selected export markets.
• New product monetization: launch of Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers (approved October 2025) to drive higher-margin consumable sales and recurring clinic replenishment.

• Controlling shareholder: Juzi Holding Co., Ltd.-increased stake to 54.66% in October 2025, indicating long-term support and access to strategic capital.
• Market capitalization: HKD 42.15 billion (as of November 14, 2025), providing balance-sheet scale to fund R&D and channel expansion.
• Analyst sentiment: consensus 'Buy' with price targets ranging HK$44.60-HK$78.00, supporting equity financing and M&A optionality.

• Leadership: significant position in China's bioactive ingredient-based professional skin treatment segment, leveraging proprietary biotech R&D and branded clinical solutions.
• Growth levers: commercialization of the recombinant collagen product, deeper penetration of existing brands across clinical channels, and expansion of device + consumables recurring revenue.
• Strategic intent: reinforce leadership in health & beauty by pairing high-efficacy ingredients with clinic-level delivery systems and broadening distribution reach.